About diabetic gastroparesis
Gastroparesis is a condition in which the stomach empties more slowly than normal or food stops moving through the digestive tract. People who have gastroparesis, also known as delayed gastric emptying, can experience nausea, vomiting, bloating after a meal, early satiety, decreased appetite, heartburn, and abdominal pain. Without treatment, gastroparesis can lead to blockages in the digestive tract, infection, dehydration, weight loss, and cause complications with diabetic medicine, making it difficult for patients with diabetes to control blood glucose levels.
Twenty-nine percent of patients with diabetes have gastroparesis.6 The disorder occurs as a result of a disruption in the normal digestive process. With gastroparesis, muscular contractions in the esophagus, stomach, and small intestine may be too slow or out of rhythm, resulting in food emptying slowly from the stomach or stopping in the digestive tract. When food stays in the stomach for too long, it can cause many uncomfortable symptoms and eventually may lead to more serious complications.
Treat diabetic gastroparesis symptoms with Metozolv ODT
Fortunately, convenient diabetic gastroparesis relief is available. Metozolv ODT can help promote muscular contractions that help increase the speed at which food moves through the digestive system, which helps alleviate your symptoms.1-4 If your diabetic gastroparesis is currently being treated with metoclopramide, talk with your healthcare professional about the benefits of Metozolv ODT, an orally disintegrating metoclopramide tablet.7
Common symptoms of diabetic gastroparesis
Learn how Metozolv ODT treats diabetic gastroparesis
Learn more about Metozolv ODT
References: 1. McCallum RW, Ricci DA, Rakatansky H, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983;6:463-467.
2. Ricci DA, Saltzman MB, Meyer C, Callachan C, McCallum RW. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol. 1985;7:25-32.
3. Snape WJ, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann Intern Med. 1982;96;444-446.
4. Erbas T, Varoglu E, Erbas B, Tastekin G, Akalin S. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care. 1993;16:1511-1514.
5. Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol. 1999;94:1230-1234.
6. Hasler WL. Gastroparesis—current concepts and considerations. Medscape J Med. 2008;10-16.
7. METOZOLV ODT [package insert]. Morrisville, NC: Salix Pharmaceuticals, Inc; 2009.
IMPORTANT SAFETY INFORMATION
Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive
dyskinesia increases with the duration of treatment and the total cumulative dose.
Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive
dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.
Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh
the risk of developing tardive dyskinesia.
METOZOLV™ ODT (metoclopramide HCl) is indicated as short-term therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD)
who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric
stasis) in adults. Therapy should not exceed 12 weeks in duration. METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage,
or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal
reactions. METOZOLV ODT should be used with caution in patients showing acute dystonic reactions, drug-induced Parkinsonism, or other extrapyramidal symptoms;
neuroleptic malignant syndrome; with a prior history of depression; hypertension; congestive heart failure and ventricular arrhythmia. Patients may experience
withdrawal symptoms after stopping the use of METOZOLV ODT.
In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.
Please see accompanying full Prescribing Information
for Metozolv ODT, including BOXED WARNING.